Drugs / SOZINIBERCEPT
SOZINIBERCEPT
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02543229 | Jul 2015 → Feb 2017 | age-related macular degeneration, ocular vascular disorder | Opthea Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03397264 | Jan 2018 → Mar 2020 | diabetic macular edema | Opthea Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03345082 | Nov 2017 → May 2019 | wet macular degeneration | Opthea Limited | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04757610 | Mar 2021 → Mar 2025 | wet macular degeneration | Opthea Limited | Terminated | No outcome recorded |
| Phase 3 | NCT04757636 | Mar 2021 → Mar 2025 | wet macular degeneration | Opthea Limited | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOZINIBERCEPT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095152 ↗ |
| Known as | OPT-302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04757610 ↗ |
| Known as | VGX-300 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095152 ↗ |
| Action | Inhibit | “It functions by binding and neutralizing the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on endogenous VEGFR-2 and VEGFR-3.” NCT02543229 ↗ |
| Modality | Protein / enzyme biologic | “OPT-302 is a soluble form of VEGFR-3 comprising the extracellular domains 1-3 of human vascular endothelial growth factor receptor (VEGFR)-3 and the Fc fragment of human IgG1.” NCT02543229 ↗ |
| Route | Intravitreal | “OPT-302 will be administered by intravitreal injection once every month for 3 months” NCT02543229 ↗ |